# RNN 1st Gen Model McKesson Corporation Drugs, proprietaries, & sundries

Prediction models:
Subscribe >> Deal exit on
Feb. 22, 2018
Deal entry on
Feb. 22, 2018
1.43%Expected margin
78.00% successful of 50 deals
$ 149.59 Last close price
at 21-feb-2018

MCK

Model's trade recommendations No return for period yet

1.72% Annual return

$30.71B Market Cap

β 1.23  

MCK

Model (following trade recommendations)

MCK

Underlying stock

S&P 500

Index
Return for period
-14.31%
1.78%
52wk return 8.85%
0.36%
16.82%
52wk Range
135.00—176.72
2000.54—2399.63
Sortino ratio 0.21
Sharpe ratio 0.17
Norm. RMSE 1.06%
Downside risk 11.89%
Volatility 15.06%
  • 1.36 (0.91%) Div (Yield)
  • BUY Analysts consensus recommendation

McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by their ICARE shared principles, their employees work every day to innovate and deliver opportunities that make their customers and partners more successful - all for the better health of patients.

Industry sector: Medical

Sector classification: Drugs, proprietaries, & sundries

Deep Learning based analysis and prediction model for McKesson Corporation (MCK) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for MCK model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 204M
P/E 11.87
Shares Outstanding 206M
% Held by Insiders 1.20%
% Held by Institutions 85.47%
EPS (last reported FY) $11.61
EPS (last reported Q) $3.41
EPS, estimated (last reported Q) $2.92
Total revenues $199 B
Net income $5 B